SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
Goodwill
and Assets
| |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
As of June 30, 2025 | |
| | | |
| | | |
| | | |
| | |
Goodwill | |
| - | | |
| 38,631 | | |
| - | | |
| 38,631 | |
Assets | |
$ | 2,411 | | |
$ | 49,071 | | |
$ | - | | |
$ | 51,482 | |
| |
| | | |
| | | |
| | | |
| | |
As of December 31, 2024 | |
| | | |
| | | |
| | | |
| | |
Goodwill | |
| - | | |
| - | | |
| - | | |
| - | |
Assets | |
$ | 3,629 | | |
$ | - | | |
$ | - | | |
$ | 3,629 | |
Segment operating results
Six months ended June 30, 2025: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
Revenues | |
$ | 1,367 | | |
$ | 152 | | |
$ | - | | |
$ | 1,519 | |
Cost of revenues | |
| 875 | | |
| 310 | | |
| - | | |
| 1,185 | |
Research and development | |
| 1,184 | | |
| 318 | | |
| - | | |
| 1,502 | |
Selling and marketing | |
| 325 | | |
| 741 | | |
| - | | |
| 1,066 | |
General and administrative | |
| 1,231 | | |
| 802 | | |
| 1,561 | | |
| 3,594 | |
Loss from operations | |
| (2,248 | ) | |
| (2,019 | ) | |
| (1,561 | ) | |
| (5,828 | ) |
Six months ended June 30, 2024: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
Revenues | |
$ | 1,738 | | |
$ | - | | |
$ | - | | |
$ | 1,738 | |
Cost of revenues | |
| 646 | | |
| - | | |
| - | | |
| 646 | |
Research and development | |
| 308 | | |
| - | | |
| - | | |
| 308 | |
Selling and marketing | |
| 364 | | |
| - | | |
| - | | |
| 364 | |
General and administrative | |
| 1,662 | | |
| - | | |
| - | | |
| 1,662 | |
Loss from operations | |
| (1,242 | ) | |
| - | | |
| - | | |
| (1,242 | ) |
Three months ended June 30, 2025: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
Revenues | |
$ | 445 | | |
$ | 49 | | |
$ | - | | |
$ | 494 | |
Cost of revenues | |
| 295 | | |
| 234 | | |
| - | | |
| 529 | |
Research and development | |
| 772 | | |
| 200 | | |
| - | | |
| 972 | |
Selling and marketing | |
| 180 | | |
| 537 | | |
| - | | |
| 717 | |
General and administrative | |
| 807 | | |
| 610 | | |
| 835 | | |
| 2,252 | |
Loss from operations | |
| (1,609 | ) | |
| (1,532 | ) | |
| (835 | ) | |
| (3,976 | ) |
Three months ended June 30, 2024: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
Revenues | |
$ | 817 | | |
$ | - | | |
$ | - | | |
$ | 817 | |
Cost of revenues | |
| 389 | | |
| - | | |
| - | | |
| 389 | |
Research and development | |
| 187 | | |
| - | | |
| - | | |
| 187 | |
Selling and marketing | |
| 199 | | |
| - | | |
| - | | |
| 199 | |
General and administrative | |
| 716 | | |
| - | | |
| - | | |
| 716 | |
Loss from operations | |
| (674 | ) | |
| - | | |
| - | | |
| (674 | ) |
|
SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS |
The
following is a summary of revenues within geographic areas:
SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
United States | |
$ | 462 | | |
$ | 794 | | |
$ | 1,448 | | |
$ | 1,698 | |
Europe | |
| 8 | | |
| - | | |
| 17 | | |
| - | |
Australia/New Zealand | |
| 20 | | |
| 8 | | |
| 39 | | |
| 13 | |
Other | |
| 4 | | |
| 15 | | |
| 15 | | |
| 27 | |
Total | |
$ | 494 | | |
$ | 817 | | |
$ | 1,519 | | |
$ | 1,738 | |
|